Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial (Q28176922)
Jump to navigation
Jump to search
scientific article (publication date: 13 March 2001)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial |
scientific article (publication date: 13 March 2001) |
Statements
Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial (English)
0 references
13 March 2001
0 references
103
0 references
10
0 references
1403-9
0 references